Edgewise Therapeutics (EWTX) Expected to Announce Quarterly Earnings on Thursday

Edgewise Therapeutics (NASDAQ:EWTX) is expected to release its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.48) per share for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 9:30 AM ET.

Edgewise Therapeutics (NASDAQ:EWTX) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.46) EPS for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.04. On average, analysts expect Edgewise Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Edgewise Therapeutics Price Performance

Shares of EWTX opened at $39.75 on Thursday. The company has a 50-day moving average of $38.20 and a two-hundred day moving average of $33.34. The stock has a market cap of $4.28 billion, a price-to-earnings ratio of -23.95 and a beta of 0.27. Edgewise Therapeutics has a one year low of $12.30 and a one year high of $48.40.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. HC Wainwright restated a “buy” rating and issued a $45.00 price target on shares of Edgewise Therapeutics in a research report on Tuesday, June 16th. Leerink Partners set a $52.00 target price on shares of Edgewise Therapeutics in a research note on Tuesday, June 16th. The Goldman Sachs Group increased their target price on Edgewise Therapeutics from $20.00 to $32.00 and gave the company a “neutral” rating in a report on Wednesday, June 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Edgewise Therapeutics in a research report on Friday, July 17th. Finally, Raymond James Financial reiterated a “strong-buy” rating and set a $66.00 price target on shares of Edgewise Therapeutics in a report on Monday, June 1st. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $48.75.

Insiders Place Their Bets

In other news, CMO Joanne M. Donovan sold 50,000 shares of the company’s stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $38.57, for a total transaction of $1,928,500.00. Following the completion of the sale, the chief marketing officer owned 4,367 shares in the company, valued at approximately $168,435.19. This represents a 91.97% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Alan J. Russell sold 200,000 shares of the stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $39.41, for a total value of $7,882,000.00. Following the transaction, the insider directly owned 24,555 shares in the company, valued at approximately $967,712.55. This represents a 89.07% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 255,230 shares of company stock valued at $9,974,147 over the last quarter. 21.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Edgewise Therapeutics

A number of large investors have recently added to or reduced their stakes in EWTX. Canada Pension Plan Investment Board acquired a new position in Edgewise Therapeutics during the second quarter valued at approximately $45,000. Jones Financial Companies Lllp bought a new stake in shares of Edgewise Therapeutics during the 1st quarter worth $47,000. Steward Partners Investment Advisory LLC grew its stake in Edgewise Therapeutics by 23.9% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 2,854 shares of the company’s stock valued at $71,000 after buying an additional 550 shares during the last quarter. Strs Ohio acquired a new position in Edgewise Therapeutics in the 1st quarter valued at $84,000. Finally, BNP Paribas Financial Markets raised its holdings in Edgewise Therapeutics by 48.9% in the 2nd quarter. BNP Paribas Financial Markets now owns 8,193 shares of the company’s stock worth $107,000 after acquiring an additional 2,689 shares during the period.

Edgewise Therapeutics Company Profile

Edgewise Therapeutics, Inc (NASDAQ: EWTX) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of precision medicines for the treatment of rare diseases. The company leverages its expertise in small-molecule chemistry and ion channel biology to address severe, unmet medical needs, particularly in the areas of kidney disorders and neuromuscular diseases.

At the core of Edgewise’s pipeline is EWTX-101, a novel, orally available inhibitor of TRPC5, a calcium channel implicated in nephrotic syndromes such as focal segmental glomerulosclerosis (FSGS) and other proteinuric kidney diseases.